Great Point Partners’s Larimar Therapeutics LRMR Stock Holding History

Great Point Partners’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-900,000	Closed	-$4.08M	–	47
2023 Q1	$4.08M	Sell	900,000 -373,635	-29%	-$1.95M	0.8%	32
2022 Q4	$5.26M	Buy	1,273,635 +138,635	+12%	+$473K	1.03%	34
2022 Q3	$3.63M	Buy	+1,135,000	New	+$2.84M	0.87%	30
2019 Q3	–	Sell	-184,266	Closed	-$2.63M	–	42
2019 Q2	$2.63M	Sell	184,266 -74,974	-29%	-$2M	0.29%	29
2019 Q1	$8.52M	Sell	259,240 -40,626	-14%	-$2.08M	0.84%	28
2018 Q4	$17.8M	Buy	299,866 +17,251	+6%	+$1.7M	2.25%	18
2018 Q3	$39.6M	Sell	282,615 -9,052	-3%	-$1.1M	6.18%	3
2018 Q2	$35.8M	Buy	+291,667	New	+$24.8M	4.96%	7
2014 Q4	–	Sell	-1,405	Closed	-$331K	–	33
2014 Q3	$331K	Buy	+1,405	New	+$318K	0.14%	37

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Great Point Partners's LRMR Position: Q2 2023 in Review

Great Point Partners sold out of Larimar Therapeutics (LRMR) in Q2 2023, closing a stake of 900,000 shares — an estimated $4.08M sold.

Great Point Partners first reported a position in LRMR in Q3 2014 and held it in 9 quarters. The position peaked at $39.6M in Q3 2018. 65 funds tracked by Wall St. Rank hold LRMR as of Q2 2023.

Great Point Partners reported no remaining Larimar Therapeutics position as of Q2 2023 after selling out during the quarter.
Great Point Partners sold 900,000 Larimar Therapeutics shares in Q2 2023, an estimated $4.08M.
Great Point Partners first reported a position in Larimar Therapeutics in Q3 2014 and held it in 9 quarters.
Great Point Partners's Larimar Therapeutics position peaked at $39.6M in Q3 2018.
65 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2023.

Based on Great Point Partners's 13F filing for Q2 2023, filed 14 Aug 2023.